Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, picking up a mid-stage ulcerative colitis and Crohn’s asset.
Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, picking up a mid-stage ulcerative colitis and Crohn’s asset.